GT316

Clinical trials for GT316 explained in plain language.

Never miss a new study

Get alerted when new GT316 trials appear

Sign up with your email to follow new studies for GT316, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Cancer-Fighting immune cell therapy trial ends early

Disease control Terminated

This trial tested a treatment that uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack advanced solid tumors. The goal was to see if it was safe and tolerable. Only 2 people took part before the study was stopped early.

Matched conditions: GT316

Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control

Last updated May 13, 2026 16:00 UTC

GT316

Get alerted when new GT316 trials appear

Cancer-Fighting immune cell therapy trial ends early